Long acting GLP-1 receptor agonist (injectable)
Polyethylene glycol loxenatide 400 µg injection once weekly
PEGLOX_SC_400UG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.83 (-1.32 to -0.34) | 0.46 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -13.86 (-18.13 to -9.75) | 1.00 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 10.27 (2.68 to 44.79) | 0.82 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.59 (0.01 to 46.06) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.57 (0.01 to 36.43) | 0.68 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.59 (0.01 to 41.91) | 0.56 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 0.06 (-9.89 to 9.59) | 0.35 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 19.62 (3.03 to 176) | 0.91 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 17.75 (3.46 to 71.92) | 0.86 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.49 (1.16 to 37.47) | 0.27 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.49 (0.36 to 78.72) | 0.37 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.60 (0.05 to 5.42) | 0.75 |